Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany: reliable data on MS incidence available from 2-year study:

This article was originally published in Clinica

Executive Summary

The German population of multiple sclerosis sufferers is currently 120,000, with 2,500 new cases recorded every year. The economic costs are some euro500m ($585m) per year in direct hospital costs and a further euro3.5bn in social benefits and other costs. A study led by Dr Peter Flachenecker, of the university hospital of Wurzburg set out to log patients at five regional centres over a two-year period, ending in December 2003. Their documentation project covered some 3,400 patients during this period allowing them to calculate new incidence as being 3 per 100,000 of population (based on observations in Rostock and Wurzburg). Newly-diagnosed MS patients were on average 30 years old. The project also revealed that two-thirds of observed patients were female; a third had limited mobility; 7% were wheelchair-bound; 1.6% were bed-bound. The register has since grown to 10,000 cases, and neurologists hope the knowledge put into this developing database will help in the management and therapy of patients.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT050745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel